^
Association details:
| Biomarker: | NPM1-ALK L1196Q |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Excerpt:
While Ba/F3 NA L1196Q are sensitive to both AP26113 and NVP-TAE684, with an IC50 of 9 nmol/L, Ba/F3 NA I1171N are resistant to both drugs, with an IC50 of 329 and 759 nmol/L, respectively.
DOI:
10.1158/1541-7786.MCR-12-0569
